PKI PerkinElmer Inc

Item 2.01. Completion of Acquisition or Disposition of Assets.

On September 17, 2021, PerkinElmer, Inc. (the “Company”), through its direct, wholly owned subsidiaries, Burton Acquisition I, Inc. ( “Merger Sub I”) and Burton Acquisition II, Inc. (“Merger Sub II” and, together with Merger Sub I, the “Merger Subs”), completed its acquisition of BioLegend, Inc. (“BioLegend”) pursuant to the Agreement and Plan of Merger dated as of July 25, 2021 (the “Merger Agreement”) by and among the Company, the Merger Subs, BioLegend and Gene Lay, solely in his capacity as the stockholder representative thereunder. On September 17, 2021, in accordance with the Merger Agreement, Merger Sub I was merged with and into BioLegend (the “First Merger”), with BioLegend surviving the First Merger as a wholly owned subsidiary of the Company, and, immediately following the First Merger, BioLegend was merged with and into Merger Sub II (the “Second Merger” and, together with the First Merger, the “Merger”), with Merger Sub II surviving the Second Merger as a wholly owned subsidiary of the Company.

In connection with the consummation of the Merger, the Company paid an aggregate purchase price of approximately $5.25 billion, subject to certain working capital and other adjustments (the “Aggregate Consideration”). The Aggregate Consideration was paid approximately 59.5% in cash and 40.5% in shares of the Company’s common stock valued at $156.3561 per share, representing the volume weighted average trading price of the Company’s common stock for the ten trading day period ending on the day immediately prior to the date the Merger Agreement was signed (the “Stock Consideration”). The Stock Consideration consisted of 14,066,771 shares of the Company’s common stock and was issued on September 17, 2021 in a private placement pursuant to an exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2) of the Securities Act.

The foregoing description of the Merger Agreement is qualified in its entirety by reference to the full text of the Merger Agreement, which is filed as Exhibit 2.1 to this Current Report on Form 8-K and is incorporated herein by reference.

As previously reported, (i) on September 10, 2021, the Company issued $500,000,000 aggregate principal amount of 0.550% Senior Notes due 2023, $800,000,000 aggregate principal amount of 0.850% Senior Notes due 2024, $500,000,000 aggregate principal amount of 1.900% Senior Notes due 2028 and $500,000,000 aggregate principal amount of 2.250% Senior Notes due 2031 in a public offering pursuant to a registration statement on Form S-3 (File No. 333-230425) and a base prospectus and a prospectus supplement related to the offering of such notes (the “Offering”), which notes were issued under an indenture, dated as of October 25, 2011 (the “Base Indenture”) by and between the Company and U.S. Bank National Association (the “Trustee”), as supplemented by a Seventh Supplemental Indenture, dated as of September 10, 2021 (the “Supplemental Indenture”) by and between the Company and the Trustee, (ii) on August 11, 2021, the Company entered into an unsecured delayed draw term loan credit facility (the “Term Loan Credit Agreement”) with Bank of America, N.A., as Administrative Agent and the Lenders party thereto, that provides for a $500 million committed term loan credit facility and (iii) on August 24, 2021,

the Company entered into an unsecured revolving credit facility (the “Revolving Credit Agreement”) with PerkinElmer Health Sciences, Inc., PerkinElmer Life Sciences International Holdings, PerkinElmer Global Holdings S.à r.l. and PerkinElmer Health Sciences B.V. as Borrowers, Bank of America, N.A. as Administrative Agent, Swing Line Lender and an L/C Issuer, the Lenders party thereto and the other L/C Issuers party thereto, that provides for a $1.5 billion committed unsecured revolving credit facility available through August 24, 2026. At the closing of the term loan credit facility and revolving credit facility, the Company did not borrow any funds under either the Term Loan Credit Agreement or the Revolving Credit Agreement.

The cash consideration payable in connection with the closing of the Merger was funded through a combination of $2.28 billion in proceeds from the Offering, a drawdown on September 16, 2021 of the full $500 million available under the Term Loan Credit Agreement, a draw on September 16, 2021 on the Revolving Credit Agreement of approximately $300 million, a portion of which was used for the Merger, and cash on hand. The description of the Offering set forth in Item 1.01 in the Company’s Current Report on Form 8-K filed on September 10, 2021, the description of the Term Loan Credit Agreement set forth in Item 1.01 in the Company’s Current Report on Form 8-K filed on August 12, 2021 and the description of the Revolving Credit Agreement set forth in Item 1.01 in the Company’s Current Report on Form 8-K filed on August 25, 2021 are incorporated herein by reference. In addition, the foregoing description of the Base Indenture is qualified in its entirety by reference to the full text of the Base Indenture, which is filed as Exhibit 4.1 to this Current Report on Form 8-K and is incorporated herein by reference, the foregoing description of the Supplemental Indenture is qualified in its entirety by reference to the full text of the Supplemental Indenture, which is filed as Exhibit 4.2 to this Current Report on Form 8-K and is incorporated herein by reference, the foregoing description of the Term Loan Credit Agreement is qualified in its entirety by reference to the full text of the Term Loan Credit Agreement, which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference, and the foregoing description of the Revolving Credit Agreement is qualified in its entirety by reference to the full text of the Revolving Credit Agreement, which is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

(d) Exhibits